Lonza Publishes 2024 Comparative Financials Under One Lonza Organizational Structure

- The One Lonza organizational structure became effective on 1 April 2025 and comprises three CDMO Business Platforms: Integrated Biologics, Advanced Synthesis and Specialized Modalities
- Lonza reports 2024 financials for the CDMO Business Platforms for sales, CORE EBITDA, CORE EBITDA margin and CapEx for the purpose of comparison ahead of reporting its Half-Year 2025 financial results
- The Capsules & Health Ingredients business continues to operate in its existing structure

Basel, Switzerland, 27 May 2025 – Prior to reporting its Half-Year Results 2025 on 23 July 2025, Lonza is today providing comparative financials for 2024 to reflect its One Lonza operating model, which **became effective** on 1 April 2025. Designed to support the One Lonza vision and strategy, the new organizational structure comprises three CDMO Business Platforms, which manage multiple technology platforms:

- **Integrated Biologics** comprises the Mammalian and Drug Product Services technologies, alongside the Licensing business
- **Advanced Synthesis** comprises the Small Molecules and Bioconjugates technologies
- **Specialized Modalities** includes the Cell & Gene, mRNA, Microbial technologies and Bioscience products

The **Capsules & Health Ingredients** business continues to operate in its existing structure.

Aligned to the One Lonza organizational structure, the updated financials for 2024 provide investors with comparable figures for the Half-Year 2025 reporting, which will be published on 23 July 2025, and the Full-Year 2025 reporting.

The **2024 Comparative Financials Report** can be viewed **here**.

About Lonza
Lonza is one of the world's largest contract development and manufacturing organizations (CDMOs) dedicated to serving the healthcare industry. Working across five continents, our global team of around 18,500 colleagues works alongside pharma and biotech companies to turn their breakthrough innovations into viable therapies. We support our customers in bringing life-saving and life-enhancing treatments to patients worldwide with a combination of cutting-edge science, smart technology and lean manufacturing.

Our company generated sales of CHF 6.6 billion with a CORE EBITDA of CHF 1.9 billion in Full-Year 2024.

Find out more at **www.lonza.com**.

Lonza Contact Details

Daniel Buchta
Head of Investor Relations
Lonza Group Ltd
Tel +41 61 316 29 85
daniel.buchta@lonza.com

Francesca Maguire
External Communications Lead
Lonza Group Ltd
francesca.maguire@lonza.com

Additional Information and Disclaimer
Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited ("SGX-ST"). Lonza Group Ltd is not subject to the SGX-ST's continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.

All trademarks belong to Lonza and are registered in CH, US and/or EU, or belong to their respective third-party owners and are used only for informational purposes.